<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80480">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737047</url>
  </required_header>
  <id_info>
    <org_study_id>CRO: 1992</org_study_id>
    <secondary_id>2012-003581-40</secondary_id>
    <nct_id>NCT01737047</nct_id>
  </id_info>
  <brief_title>A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'</brief_title>
  <acronym>POPPY</acronym>
  <official_title>A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in England and Ireland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify medical conditions that may cause particular
      problems to individuals receiving care for HIV infection over the age of 50.  In addition,
      as the effects and potentially the side effects, of HIV medication may change with age, this
      study will also investigate the association between age and differing effects of
      antiretroviral therapies such as treatment outcomes, side effects and the levels of drugs in
      blood.

      Results from this study may inform future HIV treatment guidelines on how we monitor
      individuals with HIV infection.  The results may also assist in the design of future studies
      for the treatment of diseases associated with ageing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, prospective, observational study over 3 years.

      Our study will describe the impact of advancing age on the experience of living with HIV in
      England and Ireland. To address this we will establish cohorts of HIV-positive people aged
      &gt;50 and &lt;50 years as well as demographically matched HIV-negative people aged &gt;50 years.

        1. To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people
           and their relationship with demographic/clinical factors.

        2. To evaluate associations between antiretroviral drug concentrations and age, and to
           assess the potential impact of age on drug efficacy, drug-drug interactions and
           co-morbidities.

        3. To contribute to the development and implementation of evidence-based recommendations
           for the clinical monitoring of older HIV-positive patients.

      2000 will be recruited in all either white or black african individuals (self reported) 1000
      will be Over 50 years of age and HIV positive, 500 will be under the age of 50 and will be
      HIV positive and 500 will be over the age of 50 and be HIV negative.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>clinical manifestations of ageing</measure>
    <time_frame>after 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people and their relationship with demographic/clinical factors.Comparison of three groups HIV+ve &gt;50, HIV+&lt;50 and HIV-ve &gt;50.  White or black african - analysis of demographic details and co-morbidity details collected at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>variations of anti-retroviral medication associated with age.</measure>
    <time_frame>after 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of two groups HIV+ve &gt;50 and HIV+ &lt;50 measurement of blood concentrations of HIV medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the potential impact of age on drug efficacy, drug-drug interactions and co-morbidities.</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of three groups HIV+ve &gt;50, HIV+&lt;50 and HIV-ve &gt;50. Drug related side effects collected at each visit and also Co-morbidity details collected at each visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To contribute to the development and implementation of evidence-based recommendations for the clinical monitoring of older HIV-positive patients.</measure>
    <time_frame>after 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of co-morbidities in relation to age in the three groups: HIV+ve &gt;50, HIV+ve &lt;50 and HIV -ve &gt;50.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>HIV Positive</condition>
  <condition>Ageing</condition>
  <arm_group>
    <arm_group_label>HIV positive over 50 years of age</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive under the age of 50</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative over the age of 50</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for storage Blood (serum and plasma,) and urine samples will be collected at visits 1
      and 3 stored for subsequent projects of the potential pathogenic mechanisms underlying
      age-related diseases. This will include assessment of vitamin-D and PTH and probably DNA
      analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive over 50 years HIV positive between 18 and 50 years HIV negative over 50 years
        White Black african
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Older HIV-positive cohort (n=1000):

          -  documented HIV infection

          -  age &gt;50 years at study entry

          -  self defined white or black African ethnicity

          -  likely route of HIV acquisition via sexual exposure Either by male to male exposure
             if white or by heterosexual exposure if white or black African

          -  able to comprehend study patient information leaflet

             -Younger HIV-positive cohort (n=500):

          -  documented HIV infection

          -  age &lt;50 at study entry*

          -  self defined white or black African ethnicity

          -  likely route of HIV acquisition via sexual exposure Either by male to male exposure
             if white or by heterosexual exposure if white or black African.

          -  able to comprehend study patient information leaflet

               -  this group will comprise of at least 150 subjects in each of the following age
                  groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study
                  Monitoring Team.

        HIV-negative cohort (n=500):

          -  documented negative HIV test at screening

          -  age &gt;50 years at study entry

          -  self defined white or black African ethnicity

          -  registered with a General Practitioner and gives permission for contact with that
             General Practitioner.

        Exclusion Criteria:

          -  in the opinion of the investigator, those unable or unwilling to comply with the
             requirements of the study

          -  life expectancy less than 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Sabine, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Winston, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Whitehouse, MB BS</last_name>
    <phone>00442075943413</phone>
    <email>a.whitehouse@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alan `Winston, MD</last_name>
    <phone>004420 3312 1603</phone>
    <email>a.winston@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College Dublin School of Medicine and Medical Sciences, Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liz Coghlan</last_name>
      <phone>0 353 1 7164599</phone>
      <email>Elizabeth.coghlan@ucd.ie</email>
    </contact>
    <contact_backup>
      <last_name>Patrick Mallon, MD</last_name>
      <phone>00353 1 7164495</phone>
      <email>paddy.mallon@ucd.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Paddy Mallon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicky Perry</last_name>
      <phone>01273 523079</phone>
      <email>Nicky.Perry@bsuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Martin Fisher</last_name>
      <phone>01273 664731</phone>
      <email>Martin.Fisher@bsuh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucy Campbell</last_name>
      <phone>0207 848 5776</phone>
      <email>Lucy.campbell@kcl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Frank Post, MD</last_name>
      <phone>0207 848 5779/5776</phone>
      <email>Frank.post@kcl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Post, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Winston, MD</last_name>
      <phone>020 3312 1603</phone>
      <email>a.winston@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kenneth Legg</last_name>
      <phone>020 3312 1464</phone>
      <email>k.legg@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sifiso Mguni</last_name>
      <phone>0208510 5117</phone>
      <email>Sifiso.mguni@homerton.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Anderson, MD</last_name>
      <phone>020 8510 7438</phone>
      <email>janderson@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jane Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Milinkovic</last_name>
      <phone>020 3108 2100</phone>
      <email>a.milinkovic@ucl.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ian Williams, MD</last_name>
      <phone>020 3108 2078</phone>
      <email>Ian.williams@ucl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Higgs</last_name>
      <phone>02033156135</phone>
      <email>Chris.higgs@chelwest.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Marta Boffito, MD</last_name>
      <phone>020331556507</phone>
      <email>marta.boffito@chelwest.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Marta Bofito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Ageing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
